Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2009
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirusRobin J Prestwich, Fiona Errington, Lynette P Steele, et al.Cancer Immunology Research|September 14, 2018
Antibody-Neutralized Reovirus Is Effective in Oncolytic VirotherapyRobert A Berkeley, Lynette P Steele, Aat A Mulder, et al.International Journal of Cancer|August 29, 2013
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascitesV A Jennings, E J Ilett, K J Scott, et al.Gene Therapy|April 11, 2008
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanomaF Errington, C L White, K R Twigger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replicationRobin J Prestwich, Elizabeth J Ilett, Fiona Errington, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2011
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralizationElizabeth J Ilett, Montserrat Bárcena, Fiona Errington-Mais, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Tumor infection by oncolytic reovirus primes adaptive antitumor immunityRobin J Prestwich, Fiona Errington, Elizabeth J Ilett, et al.Journal for Immunotherapy of Cancer|March 20, 2021
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow nicheLouise M E Müller, Gemma Migneco, Gina B Scott, et al.Cancer Immunology Research|April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line TreatmentLaura Evgin, Amanda L Huff, Timothy Kottke, et al.Science Translational Medicine|January 5, 2018
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockadeAdel Samson, Karen J Scott, David Taggart, et al.Pageof 2